Endocannabinoid System in Autism Development
Clinical Takeaway Maternal cannabis use during pregnancy was associated with increased behavioral and developmental concerns in children, with stronger associations observed in children who had autism spectrum disorder symptoms compared to those without.…
Endocannabinoid System and Psychosis Risk: Clinical Evidence
Clinical Takeaway Cannabis-induced psychosis increases the risk of subsequently developing schizophrenia spectrum and bipolar disorder, with prevalence rates varying significantly across studies. Patients experiencing cannabis-induced psychosis require…
Endocannabinoid System in Smoking Cessation Research
Clinical Takeaway Clinical Takeaway: Digital smoking cessation tools tailored specifically for people living with HIV can reach this high-risk population and reduce tobacco use, which remains a major cause of preventable illness and death in HIV-positive…
Endocannabinoid System Clinical Research for Autism
Clinical Takeaway Cannabis derivatives, particularly CBD-dominant formulations, show potential for reducing behavioral challenges and anxiety in autism spectrum disorder based on available clinical trials. Evidence remains limited by small sample sizes…
Endocannabinoid System in Adolescent Mental Health
Clinical Takeaway Clinical Takeaway Adolescents experiencing depression and anxiety symptoms demonstrate significantly increased risk for developing cannabis use patterns within 18 months, suggesting that untreated mental health symptoms may drive…
Endocannabinoid System & Adolescent Psychotic Disorder Risk
Clinical Takeaway Adolescents who use cannabis show increased risk of developing clinically diagnosed psychotic, bipolar, depressive, and anxiety disorders compared to non-users, with effects persisting into young adulthood. This association holds across…
Endocannabinoid System Clinical Research: AURORA Study
Clinical Takeaway Pre-trauma insomnia is an independent predictor of increased alcohol and cannabis use following traumatic injury, with this relationship partially mediated by posttraumatic stress symptoms. Trauma survivors with baseline sleep…
Endocannabinoid System Sleep Research: Clinical Trial Evidence
Clinical Takeaway This pilot study found that a single dose of 10mg THC combined with 200mg CBD reduced total sleep time by approximately 24.5 minutes in patients with insomnia disorder, contrary to expectations for a sleep aid. The combination did not…
Endocannabinoid System Cannabis Anxiety Treatment Evidence
Clinical Takeaway Clinical Takeaway: Cannabis flower products showed greater daily anxiety reduction compared to edibles in this 30-day study of adults seeking anxiety relief, though effects varied by cannabinoid composition. THC alone increased anxiety…
Endocannabinoid System Trauma Treatment and PTSD Research
Clinical Takeaway Cannabis use does not significantly impair outcomes of evidence-based trauma-focused treatments for people with co-occurring PTSD and substance use disorders. Trauma-focused therapy remains an effective approach for this population…